1123838-51-6 Usage
General Description
Glesatinib hydrochloride is a chemical compound that is a small molecule inhibitor of the Axl, Mer, and Flt3 receptor tyrosine kinases. It has shown potential as a targeted therapy for the treatment of cancers such as non-small cell lung cancer and acute myeloid leukemia. Glesatinib hydrochloride works by blocking the activity of these specific kinases, which are often overexpressed in cancer cells and contribute to tumor growth and progression. Clinical studies have demonstrated its ability to inhibit tumor growth and improve survival rates in cancer patients, making it a promising candidate for further development as a cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1123838-51-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,3,8,3 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1123838-51:
(9*1)+(8*1)+(7*2)+(6*3)+(5*8)+(4*3)+(3*8)+(2*5)+(1*1)=136
136 % 10 = 6
So 1123838-51-6 is a valid CAS Registry Number.
1123838-51-6Relevant articles and documents
PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS
-
Page/Page column 128; 131, (2009/04/25)
The invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, particularly at an industrial level The processes are aimed at ultimately forming compounds of the formula (A) where M is thieno[3,2,b]pyridinyl as shown, the group D is a ring or ring system, preferably pyridine, and the group Z, Ar, and G are as defined herein Such compounds can act to inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling.
